GC Biopharma joins CEPI-led tabletop drill to prepare for future pandemics
GC Biopharma said Monday it took part in the Korea 100Day Mission Tabletop Exercise held Feb. 5-6 and organized by the Coalition for Epidemic Preparedness Innovations, the Korea Disease Control and Prevention Agency, the Ministry of Food and Drug Safety and the International Vaccine Institute.
The scenario-based drill tested whether the full process — from vaccine development to approval, manufacturing and supply — could be completed within 100 days in a future pandemic. Organizers said the goal was to refine decision-making among the government, international organizations and vaccine makers to reduce the risk of delays during an actual outbreak.
GC Biopharma participated as a manufacturer capable of handling the full production process for messenger RNA, or mRNA, medicines, using the exercise to review its vaccine development and manufacturing capacity based on its mRNA platform. The company said the drill also included discussions on flexible approaches to clinical and regulatory procedures during a pandemic, and it expects closer coordination with the government could enable faster responses.
Kwangdong Pharmaceutical backs Ulsan children’s rights committee
Kwangdong Pharmaceutical said Monday it held a launch ceremony for the Ulsan Metropolitan City Children’s Happiness Committee with the Korea Child Abuse Prevention Association to support children’s rights protection in the region.
The company said the event included programs with children participating directly. The committee plans initiatives including child safety and anti-violence campaigns, promoting positive parenting, operating children’s rights education programs and expanding child participation in policymaking. It also plans to focus on strengthening local safety nets, including safety checks of school routes and play environments and building an early detection system for child abuse risks.
Cha Bio F&C’s Evercell launches ‘Cell Youth Plumping Ampoule’
Cha Bio F&C said Monday its premium anti-aging cosmetics brand, Evercell, launched a new product, the Evercell Cell Youth Plumping Ampoule.
The ampoule mist is a new addition to the Cell Youth line and features lactobacillus-derived exosomes and rose polydeoxyribonucleotide, or PDRN, as key ingredients. The company said it is designed to support anti-aging care and help create an immediate look of skin volume and radiance.
Cha Bio F&C said its CHA-probiotics EV Complex™, an exosome delivery ingredient, and rose PDRN help improve skin condition and support regenerative care, while 20-layer hyaluronic acid helps deliver moisture for hydration.
The product uses a dual-texture formula with separate gel and oil layers that are mixed by shaking just before use, the company said, adding that the feel can vary depending on how it is used.
Alteogen reports progress on once-monthly obesity drug candidate
Alteogen said Monday it disclosed development progress on a once-monthly obesity treatment based on its in-house ultra-long-acting platform. Built on the company’s protein engineering technology, the platform extends dosing to once a month, compared with its existing long-acting platform, NexP, which supports once-weekly dosing.
With once-weekly obesity treatments established as the standard in the global market, the company said next-generation candidates are being developed to achieve greater weight loss and improve dosing convenience.
Alteogen said a once-monthly obesity drug candidate it previously disclosed last year showed a long half-life and sustained drug concentration in animal pharmacokinetics tests. In the latest pharmacodynamics study, the company evaluated weight-loss effects and patterns of weight regain after stopping dosing in an obese rat model. It said the candidate showed weight loss comparable to the control group, retatrutide, and also showed a trend toward reduced rapid weight regain after treatment stopped.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.